A consolidated clinical signal from clinical trials, meta-analyses, and narrative reviews indicates that GLP-1 receptor agonists routinely enhance metabolic dysfunction, menstrual regularity, ovulation, and, in several instances, spontaneous conception rates in overweight or obese individuals with polycystic ovary syndrome [42]. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.